<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13410">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083107</url>
  </required_header>
  <id_info>
    <org_study_id>9021344</org_study_id>
    <nct_id>NCT02083107</nct_id>
  </id_info>
  <brief_title>Comparison Between Rectal &amp; Sublingual Misoprostol Before Caesarian Section To Reduce Intra &amp; Post-Operative Blood Loss</brief_title>
  <official_title>COMPARISON BETWEEN RECTAL &amp; SUBLINGUAL MISOPROSTOL BEFORE CAESARIAN SECTION TO REDUCE INTRA &amp; POST-OPERATIVE BLOOD LOSS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the work is to evaluate &amp; compare the effectiveness of rectally administered PGE1
      synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol
      before caesarean section to decrease blood loss during and after the operation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>at time of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of side effects of the drug will be noted for all cases. Postoperative bowel habits. Postoperative pain. APGAR score. The need for extra ecbolics. The need for extra analgesics.</measure>
    <time_frame>first day postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in hemoglobin concentration and hematocrite value</measure>
    <time_frame>24 hours postoperative</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>sublingual misoprostol &amp; rectal placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rectal &amp; sublingual placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive rectal placebo&quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rectal misoprostol &amp; sublingual placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Comparison of different routes of administration of 400 micro gram misoprostol</description>
    <arm_group_label>sublingual misoprostol &amp; rectal placebo</arm_group_label>
    <arm_group_label>rectal misoprostol &amp; sublingual placebo</arm_group_label>
    <other_name>Misotac</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients booked for elective cesarean section.

          2. Singleton pregnancies. 3- Full term pregnancies (GA 37-42 weeks). 4- Patients with
             only previous one cesarian section

        Exclusion Criteria:

          1. Primigravida.

          2. Blood dyscrasias.

          3. Large fibroids.

          4. Multiple pregnancies.

          5. Overdistended uterus eg. Hydramnios.

          6. Pre-eclampsia.

          7. Marked maternal anemia (Preoperative hemoglobin &lt; 9 gm/dl).

          8. Previous history of PPH.

          9. Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma
             or allergy to misoprostol.

         10. Placenta previa.

         11. Contraindication to spinal anesthesia.

         12. Previous myomectomy.

         13. Previous two or more C.S.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S. Sweed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mourad M. El-Said, Professor</last_name>
    <role>Study Director</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amgad E. Abou-Gamrah, Ass.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>AinShams university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haitham El-Sabe, MD</last_name>
    <role>Study Director</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed M. AbdEl-Hamid, Registrar</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Mohamed S. Sweed, Lecturer of Obstetrics &amp;Gynecology, Ain Shams University</investigator_title>
  </responsible_party>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Intrapartum blood loss</keyword>
  <keyword>Misoprostol</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
